UEG Week Recordings UEG Week Posters Online courses Guidelines Mistakes in... Podcasts Webinars
new
Gut Guide online
Visit ueg.eu Create myUEG account Log In
Visit ueg.eu Create myUEG account Log In

Filters:

UEG Online Course
not accredited
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Gastrointestinal Neuroendocrine Tumours

Dalvinder Mandair, Christos Toumpanakis, Martyn E Caplin

Summary

AI Generated

This online course covers the classification, diagnosis, staging, and management of gastric, duodenal, and rectal neuroendocrine tumours, which are increasingly detected during endoscopy despite being rare.

  • Neuroendocrine tumours develop from enterochromaffin cells throughout the gastrointestinal tract, with most arising in the gastro-entero-pancreatic tract
  • Although rare, the incidence of NETs is increasing and their prevalence is high due to prolonged patient survival
  • Prognosis and treatment options vary according to tumour size, grade/stage, and functionality, making correct diagnosis and staging key
  • The course teaches recognition of endoscopic features indicating NETs, required diagnostic investigations, classification systems, and identification of patients requiring specialist centre referral
  • The course is designed for gastroenterologists, nurse endoscopists, gastrointestinal and colorectal surgeons, as well as trainees and medical students
Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Overview

Neuroendocrine tumours (NETs) develop from enterochromaffin cells, which are located throughout the gastrointestinal tract. Most NETs arise in the gastro-entero-pancreatic tract (GEP-NETs) and they are increasingly found during endoscopic investigation. Although rare, the incidence of NETs is increasing, and prolonged patient survival means that their prevalence is high. Prognosis and treatment options vary according to the size, grade/stage and functionality of the NET, making correct diagnosis and staging key.

In this online course, Dalvinder Mandair, Christos Toumpanakis and Martyn Caplin cover all aspects of gastric NETs, duodenal NETs and rectal NETs—their pathogenesis, investigation, diagnosis, classification, staging, management and prognosis.  

Learning objectives

  • To develop an understanding of the classification of gastric, duodenal and rectal neuroendocrine tumours (NETs)
  • To recognise the endoscopic features that may indicate the presence of a NET
  • To learn which investigations are required as part of the diagnostic work-up
  • To identify the patients that need to be referred to a specialist NET centre

Target audience

This course is suitable for gastroenterologists, nurse endoscopists, upper gastrointestinal surgeons and colorectal surgeons, but is also appropriate for trainees and medical students.

Event

Gastrointestinal Neuroendocrine Tumours

Topics

Digestive Oncology

Accreditation status

not accredited

Duration

1 hour

Published

2019

More Like This:

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Umud Mahmudov Umud Mahmudov, Colm O'Morain, Gülüstan Babayeva, Ulvi Machanov, Javier P. Gisbert, Francis Mégraud, Olga P. Nyssen, Leticia Moreira Ruiz, Pablo Parra, Anna Cano Català, Hikmat Ibrahimli, Rashad Hasanov, Surayya Ismayilova, Ziyad Zalov, Habil Huseynov, Rovshan Ibishev, Emin Verdiyev, Farid Guliyev, Emin Mammadov

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

Liat Deutsch Liat Deutsch, Oren Shibolet, Yami Shapira, dor Shirin

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

Treating obesity: From mechanism to personalization

Treating obesity: From mechanism to personalization

Amalia Gastaldelli Amalia Gastaldelli

UEG Online Course
accredited
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Management of early-invasive (T1) colorectal cancer

Alexandra Langers, Jurjen J. Boonstra, James Hardwick

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Overview

With the introduction of population-based screening programs in several countries, the proportion of patients diagnosed with early invasive colorectal cancer (T1 CRC) has been vastly increasing. There are several major challenges in clinical management of this patient group, resulting in significant practice variations among physicians.

This online course covers the most relevant aspects of clinical management of T1 CRC patients, and provides an overview of latest insights and current knowledge gaps. To facilitate the learning process, several questions on real-life patient cases have been included in which learners can bring the acquired knowledge directly into practice.

Learning objectives

  • To systematically assess colorectal lesions and identify those suspicious for submucosally invasive (T1) cancer
  • To learn about local resection techniques for T1 colorectal cancer
  • To gain insight into histological assessment of local en bloc resection specimens of T1 colorectal cancer
  • To be aware of considerations from the oncological and patient perspective in therapeutic decision making after local treatment for T1 colorectal cancer

Target audience

This course is suitable for gastroenterologists, surgeons, pathologists, nurses and any other healthcare professionals interested in, or actively involved in clinical management of T1 CRC patients. 

This course was developed by Alexandra M.J. Langers, Jurjen J. Boonstra, James C.H. Hardwick, Richard (H.) Dang et al. in receipt of an Activity Grant from UEG.

Reviewed & updated December 2022

Event

Management of early-invasive (T1) colorectal cancer

Topics

Digestive Oncology

Accreditation status

accredited

Duration

1 hour

Published

2020

More Like This:

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Umud Mahmudov Umud Mahmudov, Colm O'Morain, Gülüstan Babayeva, Ulvi Machanov, Javier P. Gisbert, Francis Mégraud, Olga P. Nyssen, Leticia Moreira Ruiz, Pablo Parra, Anna Cano Català, Hikmat Ibrahimli, Rashad Hasanov, Surayya Ismayilova, Ziyad Zalov, Habil Huseynov, Rovshan Ibishev, Emin Verdiyev, Farid Guliyev, Emin Mammadov

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

Liat Deutsch Liat Deutsch, Oren Shibolet, Yami Shapira, dor Shirin

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

Treating obesity: From mechanism to personalization

Treating obesity: From mechanism to personalization

Amalia Gastaldelli Amalia Gastaldelli

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Event

UEG Week Barcelona 2026

Topics

Digestive Oncology Surgery Pancreas Mechanisms & Personalised Medicine

Session

Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Umud Mahmudov Umud Mahmudov, Colm O'Morain, Gülüstan Babayeva, Ulvi Machanov, Javier P. Gisbert, Francis Mégraud, Olga P. Nyssen, Leticia Moreira Ruiz, Pablo Parra, Anna Cano Català, Hikmat Ibrahimli, Rashad Hasanov, Surayya Ismayilova, Ziyad Zalov, Habil Huseynov, Rovshan Ibishev, Emin Verdiyev, Farid Guliyev, Emin Mammadov

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

Liat Deutsch Liat Deutsch, Oren Shibolet, Yami Shapira, dor Shirin

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

Treating obesity: From mechanism to personalization

Treating obesity: From mechanism to personalization

Amalia Gastaldelli Amalia Gastaldelli

UEG Poster
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Gülüstan Babayeva 1, Umud Mahmudov 2, Emin Mammadov 1,3, Farid Guliyev 4, Emin Verdiyev 5, Ulvi Machanov 6, Rovshan Ibishev 7, Habil Huseynov 8, Ziyad Zalov 9, Surayya Ismayilova 10, Rashad Hasanov 1,11, Hikmat Ibrahimli 1, Anna Cano Català 12, Pablo Parra 13, Leticia Moreira Ruiz 14, Olga P. Nyssen 13, Francis Mégraud 15, Colm O'Morain 16, Javier P. Gisbert 13

Affiliations

1 Azerbaijan State Advanced Training Institute for doctors named after A.ALIYEV, Baku, Azerbaijan

2 Modern Hospital, Baku, Azerbaijan

3 MediLand Hospital, Baku, Azerbaijan

4 National Centre of Oncology,, Baku, Azerbaijan

5 Central Hospital, Baku, Azerbaijan

6 Ganja International Hospital, Ganja, Azerbaijan

7 Zafaran Hospital, Baku, Azerbaijan

8 Azerbaijan Medical University, Oncology clinic, Baku, Azerbaijan

9 Istanbul NS Klinika, Baku, Azerbaijan

10 StarLab Medical Center, Baku, Azerbaijan

11 German Hospital, Baku, Azerbaijan

12 GOES research group, Althaia Xarxa Assistencial Universitària de Manresa,, Manresa, Spain

13 Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain

14 Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), IDIBAPS (Institut d’Investigacions Biomèdiques August Pi i Sunyer), University of Barcelona, Barcelona, Spain

15 INSERM U1312, Université de Bordeaux, Bordeaux, France

16 Trinity College Dublin, Dublin, Ireland

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

​Gastric lesions associated with Helicobacter pylori, eradication issues and problems of its sometimes-insufficient effectiveness continue to remain one of the most pressing topics in modern healthcare.

Aims & Methods

The analysis aimed to assess the usage, efficacy, and safety of initial empirical treatment for H. pylori infection in Azerbaijan.
​Data were collected at e-CRF AEG-REDCap from the European Registry on Helicobacter pylori Management (Hp-EuReg) and quality reviewed from January 2020 to May 2023. All treatment-naïve cases were assessed for effectiveness by modified intention-to-treat (mITT), per-protocol (PP) analyses, and a separate multivariate analysis was performed.

Results

The study included 3,898 patients (67% reported dyspepsia). In 1.9% of patients, at least one type of allergy was reported (1.6% to penicillin). A total of 226 patients (5.8%) received concurrent medication: PPI (5.1% on demand, 0.1% daily), aceltylsalicylic acid (1.2% on demand, 0.2% daily), NSAIDs (1.3% on demand), statins (1.2% on demand, 0.1% daily). The most frequent indication for treatment was dyspepsia with normal endoscopy in 2,610 patients (67%). In total, 3,853 (99%) patients were diagnosed pre-treatment using the rapid urease test, which was the most frequently used. The following tests were likewise used in a lower number of cases: monoclonal stool antigen test (MSAT)(0.7%) and polyclonal stool antigen test (0.1%). In 2,661 (68%) cases a MSAT was used, being the most frequent post-treatment confirmation method. Additionally, in 55 (1.4%) cases an invasive method, that is endoscopy, was performed, to confirm the eradication. First-line empirical treatment prescriptions and mITT effectiveness by treatment schemes is presented in Table 1.
Triple regimens were the most frequently prescribed in over 3,000 (82%) patients, where the PPI-C+A treatment scheme represented 54% of the total of first-line prescriptions. Treatment length varied from 14 days in 56% of cases, 10 days in 27%, and 7 days in 17%. Following 14-day treatments prescriptions achieved optimal (>90%) mITT effectiveness: PPI-C+A (94%), PPI-C+M (97%), PPI-C+M+ B (96%) and PPI-C+A+B (98%). Following schemes also provided optimal results when combined with standard-dose (i.e., 40 mg omeprazole equivalent twice a day) PPIs: PPI-A+Tc (100%) and PPI-C+A+B (96%). Additionally, prescriptions concomitantly administered with high-dose (i.e., 80 mg omeprazole equivalent twice a day) PPIs provided also over 90% eradication rates: PPI-C+A (94%), PPI-C+M (97%), PPI-C+M+B(100%) and PPI-C+A+B (99%). Compliance with treatment was over 90% in the vast majority of cases. The incidence of at least one adverse event was reported in 12% of cases.
Table 1. Most frequent first-line empirical treatment prescriptions and modified intention-to-treat effectiveness in Azerbaijan.

A-amoxicillin,
C- clarithromycin,
M- metronidazole,
L- levofloxacin,
Tc- tetracycline,
B - bismuth


mITT- modified Intention-to-treat;
PP: per protocol analysis;
low-dose PPI, between 4.5 and 27 mg omeprazole equivalents given twice a day;
standard-dose PPI, between 32 and 40 mg omeprazole equivalents given twice a day;


high-dose PPI, between 54 and 128 mg omeprazole equivalents given twice a day;
NA: not available data.
Treatment
Number of prescriptions
Use (%)
mITT,
N (%)
PP,
N (%)
mITT,
N (%)
Low-dose PPI
mITT,
N (%)
Standard-dose PPI
mITT,
N (%)
High-dose PPI
Triple-C+A
2,117
54.3
1,832 (91,2%)
1,819 (95.2%)
873 (91.2%)
527 (89.3%)
420 (93.8%)
Triple-C+M
760
19.5
584 (93,3%)
581 (96.5%)
326 (93.4%)
89 (86.4%)
167 (97.1%)
Quadruple-C+A+B
610
15.6
579 (98%)
574 (99.8%)
219 (98.2%)
187 (96.4%)
178 (99.4%)
Triple-A+L
159
4.1
124 (82,1%)
124 (99.2%)
52 (82.5%)
68 (81.9%)
4 (80.0%)
Triple-A+Tc75
1.9
71 (94,7%)
71 (100.0%)
28 (93.3%)
43 (95.6%)
NA
Quadruple-C+M+B
44
1.1
40 (95,2%)
40 (100.0%)
26 (100.0%)
6 (75.0%)
8 (100.0%)
Other
44
1.1
114 (90,5%)
113 (97.4%)
55 (93.2%)
55 (90.2%)
4 (66.7%)
Total
3,809
97.6
3,344 (92.4%)
3,322 (96.6%)
68 (92.5%)
975 (89.9%)
776 (95.4%)

Conclusion

The prescribed H. pylori eradication regimens during the period 2020–2023 in Azerbaijan adhered only partially to the Maastricht VI recommendations; however, most of first-line empirical therapies achieved high (≥90%) cure rates, providing a good safety profile.

Conference

UEG Week Vienna 2024

Topics

Stomach & H. Pylori

Submission format

Abstract

Session

H.PYLORI (Posters)

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

More Like This:

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Umud Mahmudov Umud Mahmudov, Colm O'Morain, Gülüstan Babayeva, Ulvi Machanov, Javier P. Gisbert, Francis Mégraud, Olga P. Nyssen, Leticia Moreira Ruiz, Pablo Parra, Anna Cano Català, Hikmat Ibrahimli, Rashad Hasanov, Surayya Ismayilova, Ziyad Zalov, Habil Huseynov, Rovshan Ibishev, Emin Verdiyev, Farid Guliyev, Emin Mammadov

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

Liat Deutsch Liat Deutsch, Oren Shibolet, Yami Shapira, dor Shirin

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

Treating obesity: From mechanism to personalization

Treating obesity: From mechanism to personalization

Amalia Gastaldelli Amalia Gastaldelli

UEG Poster
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

dor Shirin 1,2, Yami Shapira 1,2, Oren Shibolet 1,2, Liat Deutsch 1,2

Affiliations

1 Tel-Aviv Sourasky Medical center, Tel-aviv, Israel

2 Tel-Aviv University, Tel-Aviv, Israel

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease in which muscle weakness develops insidiously. In advanced stages of the disease dysphagia, weight loss and malnutrition occur in the majority of patients. Thus, the consideration of Percutaneous Endoscopic Gastrostomy (PEG) tube placement is common. However, the optimal timing and setting for the procedure as well desired spirometry results are either are not stated in most guidelines or debated. Previous studies have suggested greater procedural risk for patients whose forced vital capacity (FVC) was less than 50% than predicted

Aims & Methods

The aim of this study was to assess the safety of our tertiary center simplified approach to PEG tube placement in patients with ALS.
The electronical records of patients who underwent percutaneous endoscopic gastrostomy (PEG) placement between 1.1.2020 to 1.1.2023 were retrospectively reviewed. All adult patients diagnosed with ALS who underwent ambulatory PEG tube placement were included. Patients who underwent PEG tube placement during hospitalization due to acute illness were excluded. The common practice of our center regarding PEG placement in patients with ALS is as follows: initial evaluation at the Gastroenterology clinic of patients referred by the neurology clinic, followed by ambulatory PEG placement under sedation by an anesthesiologist. We collected baseline information from the neurology and gastroenterology clinic visits regarding comorbidities and baseline FVC and the functional rating score [ALS-FRS, 0-48 points, lower score indicating a more severe disease). The data concerning the procedure and possible complications were collected from endoscopy reports, emergency department visits and clinic visits after the procedure.

Results

Six hundred and sixty patients had underwent PEG tube placement in our center during study period. Of them, 67 patients had an established diagnosis of ALS (10.2%). One patient was excluded due to PEG placement in the setting of an acute illness during admission, thus 66 patients were included (mean age at PEG placement 63.5±12.7 years and 37.8% were females). Mean ALS-FRS score was 23.6±8.81 and mean FVC was 49.8±19.45% of predicted. More than half (54.7%) of the patients were using non-invasive ventilation support device at home prior to the procedure and 12.1% of patients had underwent endotracheal tube placement prior to PEG tube placement.
The averaged duration of PEG tube placement was 11.96±5.3 minutes. All PEG procedures were completed successfully. Complications were documented during two PEG placements (3%): one patient suffered from aspiration and was hospitalized and later diagnosed with aspiration pneumonia and the second patient suffered from gastric perforation and peritonitis which was diagnosed a few hours after the procedure. During the 30 days following PEG placement, 3 (4.5%) complications were documented: Two patients (3%) suffered from PEG site infections and were treated with antibiotics and one (1.5%) was diagnosed with aspiration pneumonia. No deaths occurred during the procedure or during the 30 days that followed.

Conclusion

The simple straight forward approach to PEG placement in our institution was successful and safe in the vast majority of cases. The complications rate in our cohort is comparable to other studies, even though the patients in our cohort had significantly reduced lung function and functional scores then accepted in the common practice.

References

  1. Miller R G, Jackson C E, Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, 2009 Oct 13;73(15):1218-26
  2. EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis: Andersen P M, Abrahams S, EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force, Eur J Neurol 2012 Mar;19(3):360-75.
  3. Korner S, Hendricks M, Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options, BMC Neurol 13, 84 (2013).
  4. Russ K B, Phillips MC, Percutaneous Endoscopic Gastrostomy in Amyotrophic Lateral Sclerosis, Am J Med Sci . 2015 Aug;350(2):95-7.
  5. Gregory S, Siderowf A, Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival, Neurology . 2002 Feb 12;58(3):485-7.
  6. Thomas K, Schrager J, Percutaneous endoscopic gastrostomy tube placement in amyotrophic lateral sclerosis: a case series with a multidisciplinary, team-based approach, Ann Gastroenterol 2020 Sep-Oct;33(5):480-484

Conference

UEG Week Copenhagen 2023

Topics

Small Intestine & Nutrition

Submission format

Abstract

Session

PP 04 Nutrition (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

More Like This:

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Umud Mahmudov Umud Mahmudov, Colm O'Morain, Gülüstan Babayeva, Ulvi Machanov, Javier P. Gisbert, Francis Mégraud, Olga P. Nyssen, Leticia Moreira Ruiz, Pablo Parra, Anna Cano Català, Hikmat Ibrahimli, Rashad Hasanov, Surayya Ismayilova, Ziyad Zalov, Habil Huseynov, Rovshan Ibishev, Emin Verdiyev, Farid Guliyev, Emin Mammadov

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

Liat Deutsch Liat Deutsch, Oren Shibolet, Yami Shapira, dor Shirin

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

Treating obesity: From mechanism to personalization

Treating obesity: From mechanism to personalization

Amalia Gastaldelli Amalia Gastaldelli

UEG Podcast Episode
UEG Podcast
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Mary Phillips, Leigh Donnelly

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Topics

Primary Care

Published

2025

More Like This:

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Umud Mahmudov Umud Mahmudov, Colm O'Morain, Gülüstan Babayeva, Ulvi Machanov, Javier P. Gisbert, Francis Mégraud, Olga P. Nyssen, Leticia Moreira Ruiz, Pablo Parra, Anna Cano Català, Hikmat Ibrahimli, Rashad Hasanov, Surayya Ismayilova, Ziyad Zalov, Habil Huseynov, Rovshan Ibishev, Emin Verdiyev, Farid Guliyev, Emin Mammadov

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

Liat Deutsch Liat Deutsch, Oren Shibolet, Yami Shapira, dor Shirin

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

Treating obesity: From mechanism to personalization

Treating obesity: From mechanism to personalization

Amalia Gastaldelli Amalia Gastaldelli

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
Treating obesity: From mechanism to personalization

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Treating obesity: From mechanism to personalization

Amalia Gastaldelli 1

Affiliations

1 Institute of Clinical Physiology, Pisa, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Event

UEG Week Barcelona 2026

Topics

Hepatobiliary Small Intestine & Nutrition Mechanisms & Personalised Medicine

Session

Therapy update: Anti-obesity

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Management of early-invasive (T1) colorectal cancer

Management of early-invasive (T1) colorectal cancer

James Hardwick James Hardwick, Jurjen J. Boonstra, Alexandra Langers

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

Panel discussion: Future treatment for resectable pancreatic cancer: Cut, treat or personalise?

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

EFFECTIVENESS OF FIRST-LINE EMPIRICAL TREATMENT IN AZERBAIJAN: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Umud Mahmudov Umud Mahmudov, Colm O'Morain, Gülüstan Babayeva, Ulvi Machanov, Javier P. Gisbert, Francis Mégraud, Olga P. Nyssen, Leticia Moreira Ruiz, Pablo Parra, Anna Cano Català, Hikmat Ibrahimli, Rashad Hasanov, Surayya Ismayilova, Ziyad Zalov, Habil Huseynov, Rovshan Ibishev, Emin Verdiyev, Farid Guliyev, Emin Mammadov

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

A SIMPLIFIED APPROACH TO PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE PLACEMENT IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS – SAFETY AND COMPLICATIONS

Liat Deutsch Liat Deutsch, Oren Shibolet, Yami Shapira, dor Shirin

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Best of UEG Week - Nursing with Mary Phillips and Leigh Donnelly

Leigh Donnelly Leigh Donnelly, Mary Phillips

Treating obesity: From mechanism to personalization

Treating obesity: From mechanism to personalization

Amalia Gastaldelli Amalia Gastaldelli

The global reference point for the digestive health community

Platform Publisher

United European Gastroenterology

Wickenburggasse 1 1080 Vienna, Austria

Contact us

support@ueg.eu

ueg.eu

T: +43 1 997 1639

Legal

Terms & Conditions

Imprint

Privacy Policy

Explore

My Bookmarks

My recommendations

My fields of interest

© 2026 United European Gastroenterology

Change fields of interest

These fields are selected based on the interests in your myUEG profile.
Click the item to unselect it. You can select multiple items.